Noradrenaline (Tartrate) (Sans Sulfites) Aguettant (Noradrenaline Tartrate)

Norepinephrine tartrate directly stimulates alpha‑1 adrenergic receptors on vascular smooth muscle, causing potent vasoconstriction and an increase in systemic vascular resistance. It also activates beta‑1 receptors in the heart, modestly enhancing contractility and heart rate, together resulting in elevated mean arterial pressure.

The dose of Noradrenaline (Tartrate) is individualized and set by the prescribing clinician. It is typically titrated by continuous intravenous infusion, guided by real‑time blood pressure measurements and the patient’s hemodynamic response, rather than a fixed standard regimen.

Safety data for norepinephrine tartrate in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and it should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Norepinephrine tartrate has both alpha‑1 and beta‑1 activity, offering vasoconstriction plus modest cardiac stimulation, whereas phenylephrine is a pure alpha‑1 agonist and may reduce heart rate. Clinicians often prefer norepinephrine for septic shock because its combined actions better maintain cardiac output while raising blood pressure.

The solution should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial, and avoid prolonged exposure to temperatures above the recommended range to preserve stability.

Noradrenaline (Tartrate) is supplied as a sterile solution for intravenous infusion. It is typically administered through a calibrated infusion pump, allowing precise titration of the infusion rate based on continuous hemodynamic monitoring.

Serious risks include cardiac arrhythmias, severe hypertension, and tissue necrosis if the drug extravasates from the vein. Continuous cardiovascular monitoring and careful intravenous access management are essential to detect and mitigate these complications promptly.

Patients with known hypersensitivity to norepinephrine or any component of the formulation should not receive the product. Caution is also advised in individuals with severe peripheral vascular disease, uncontrolled hypertension, or those receiving other potent vasoconstrictors without clear clinical justification.